Replimune Group Inc
NASDAQ:REPL
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (14.3), the stock would be worth $-84.85 (1 155% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1.4 | $8.04 |
0%
|
| Industry Average | 14.3 | $-84.85 |
-1 155%
|
| Country Average | 19.6 | $-116.64 |
-1 551%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Replimune Group Inc
NASDAQ:REPL
|
640.2m USD | -1.4 | -2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -191 955.6 | -159 901.4 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.8B USD | 23.2 | 168.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.7B USD | 15 | 26.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
188B USD | 15 | 22 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119B USD | 24 | 30.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -566.3 | -534.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD | 15.8 | 18.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
74.1B AUD | 14.7 | 17.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44.2B EUR | 60.6 | 34.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.2 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Replimune Group Inc
Glance View
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. The company is headquartered in Woburn, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2018-07-20. The firm is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The firm applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The firm is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1 (vusolimogene oderparepvec), RP2, and RP3. The firm is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.
